Conducting an observational study during an economic crisis: analysis of the treatment and follow-up phase of Greek patients participating in the ExFOS study
- 57 Downloads
We present the subanalysis of the Greek cohort of the Extended Forsteo Observational Study (ExFOS), a multicenter, non-interventional, prospective, observational study evaluating the effect of teriparatide on fractures, back pain (BP), health-related quality of life (HR-QoL), and safety and compliance, in patients with osteoporosis treated for up to 24 months, with a post-treatment follow-up of at least 18 months.
A total of 439 osteoporotic patients (92.2% female) were enrolled in Greece. New or worsened fractures, based on their physicians’ assessment, as well as patients’ self-assessment of HR-QoL and BP, compliance, and safety profile, were captured by validated questionnaires.
In the ExFOS Greek cohort, fracture rates were low and mean bone mineral density (BMD) was numerically improved. Compliance with teriparatide remained high throughout the study, with 81.5% of subjects completing treatment. Only 0.7% of patients reported discontinuation due to adverse effects. A sustainable improvement in patient-perceived BP and HRQoL throughout treatment and follow-up was similar to that achieved by the European Forsteo Observational Study (EFOS). A lower than expected percentage of patients using antiresorptives following teriparatide was recorded.
ExFOS reproduces the outcomes of EFOS, with a 6.5-year time interval between studies, in comparable cohorts of osteoporotic patients. Data should be interpreted in the context of observational study data collection, although summary statistics computed at each time point may overstate drug effect.
KeywordsOsteoporosis Teriparatide Back pain Quality of life Fractures
We extend our thanks to the Greek ExFOS Study Group: Adam A, Alexandridis T, Athanasakopoulos P, Dimopoulos N, Dionyssiotis Y, Georgountzos A, Giannadakis P, Gkouvas G, Kapetanos G, Kaplanoglou T, Karagiannis A, Kleisiounis A, Kokkoris P, Kosmidis C, Kossyvakis K, Krallis N, Matsouka A, Matzaroglou C, Meleteas E, Milonas C, Mpintas S, Papaioannou N, Papazisis Z, Repousis AP, Savvidis M, Temekonidis T, Trovas G, Tsakiri V, Tzoitou M, Tzoutzopoulos A, Vandoros G, Ziambaras K.
The authors wish to thank Christopher Jeremy Child PhD, Research Advisor—Endocrinology for editing the manuscript.
Compliance with ethical standards
KA and VD are employees of Pharmaserve-Lilly SACI.
- 5.Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230–240Google Scholar
- 14.Napoli N, Langdahl BL, Ljunggren O et al (2018) Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European Extended Forsteo(R) Observational Study (ExFOS). Calcif Tissue Int 16. https://doi.org/10.1007/s00223-018-0437-x
- 15.Aloumanis K, Karras D, Drossinos V, Korelis E, Polydorakis A (2011) Fracture incidence, quality of life, and back pain during 18-months treatment with teriparatide in Greek postmenopausal women with osteoporosis: results from the European Forsteo Observational Study. J Osteoporos 510398Google Scholar
- 16.Aloumanis K, Drossinos V, Trikka D, Karras D (2012) The European Forsteo Observational Study (EFOS). 18-month follow-up of Greek women completing teriparatide treatment for osteoporosis. Archives of Hellenic. Medicine 29(4):454–460 [Greek]Google Scholar
- 19.Aloumanis K, Drossinos V, Hondrelis J, Disch D (2018) Treatment outcomes after teriparatide use in Greece: country subanalysis of the EFOS and ExFOS combined Observational Studies WCO-IOF-ESCEO-2018 2018; abstr. P428. Osteoporos Int 29(1)Google Scholar